Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rassool

Showing results (211-220 of 222) with videos related to

Pageof 23
Sort By:
Trials|June 6, 2023
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosisA Dierig, M Hoelscher, S Schultz, et al.
The Lancet. Respiratory Medicine|October 4, 2024
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Andrew J Nunn, Sarah K Meredith, et al.
Southern African Journal of HIV Medicine|October 26, 2020
Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 updateJeremy Nel, Sipho Dlamini, Graeme Meintjes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2015
Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical TrialRami Kantor, Laura Smeaton, Saran Vardhanabhuti, et al.
Cancer Cell|March 24, 2012
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cellsHsing-Chen Tsai, Huili Li, Leander Van Neste, et al.
The Lancet. HIV|November 28, 2025
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort studyJean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, et al.
The Lancet. Infectious Diseases|July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trialLilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in CancerLora Stojanovic, Rachel Abbotts, Kaushlendra Tripathi, et al.
Cancer Research|January 13, 2025
ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in CancerLora Stojanovic, Rachel Abbotts, Kaushelendra Tripathi, et al.
Trials|February 26, 2026
panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbeD Mudzengi, S Mashatole, Q Xiang, et al.
Pageof 23

Showing results (211-220 of 222) with videos related to

Sort By:
Pageof 23
Trials|June 6, 2023
A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosisA Dierig, M Hoelscher, S Schultz, et al.
The Lancet. Respiratory Medicine|October 4, 2024
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trialRuth L Goodall, Andrew J Nunn, Sarah K Meredith, et al.
Southern African Journal of HIV Medicine|October 26, 2020
Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 updateJeremy Nel, Sipho Dlamini, Graeme Meintjes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 15, 2015
Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical TrialRami Kantor, Laura Smeaton, Saran Vardhanabhuti, et al.
Cancer Cell|March 24, 2012
Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cellsHsing-Chen Tsai, Huili Li, Leander Van Neste, et al.
The Lancet. HIV|November 28, 2025
Virological and drug-resistance outcomes for people living with HIV initiating or switching to tenofovir, lamivudine, and dolutegravir in six PEPFAR-supported countries: a prospective cohort studyJean Bernard Marc, Caitlyn McCarthy, Carole L Wallis, et al.
The Lancet. Infectious Diseases|July 11, 2025
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trialLilian Tina Minja, Isabella van der Feltz, Christina Manyama, et al.
Biorxiv : the Preprint Server for Biology|November 1, 2024
ZNFX1 is a Novel Master Regulator in Epigenetically-induced Pathogen Mimicry and Inflammasome Signaling in CancerLora Stojanovic, Rachel Abbotts, Kaushlendra Tripathi, et al.
Cancer Research|January 13, 2025
ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in CancerLora Stojanovic, Rachel Abbotts, Kaushelendra Tripathi, et al.
Trials|February 26, 2026
panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbeD Mudzengi, S Mashatole, Q Xiang, et al.
Pageof 23